Regulation (EC) No 141/2000: EU orphan medicines

European Union, regulation. Regulation (EC) No 141/2000 of 16 December 1999 on orphan medicinal products applied from April 2000 and created the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency. Primary text: EUR-Lex; the EMA's orphan designation pages explain the procedure.

What it grants: a medicine for a life-threatening or chronically debilitating condition affecting not more than 5 in 10,000 people in the Union (or one unlikely to be developed without incentives), and for which no satisfactory method exists or which offers significant benefit, may be designated orphan. On authorisation it receives ten years of market exclusivity against similar medicines for the same indication, reducible to six if the criteria are no longer met and extendable by two years for completing an agreed paediatric investigation plan, along with fee reductions and protocol assistance. Oncology accounts for the largest share of designations, and drugs such as imatinib, lenalidomide, and the CAR-T products entered Europe as orphans.

The arguments: the Commission's 2020 evaluation found the regulation had brought medicines that would not otherwise exist but also rewarded products with high revenues and sliced common cancers into subtypes to qualify. The 2023 pharmaceutical package proposes a modulated exclusivity (a shorter baseline with extensions for addressing high unmet need or for launching Union-wide) and a tighter test of significant benefit, which patient groups and industry contest from opposite directions. Germany's AMNOG law separately presumes added benefit for orphan medicines below a revenue threshold.